➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
McKinsey
Baxter
Johnson and Johnson
Merck

Last Updated: March 6, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR REMDESIVIR

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Remdesivir

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03719586 Investigational Therapeutics for the Treatment of People With Ebola Virus Disease Recruiting National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 2018-10-30 Background: Ebola virus can cause serious illness or death. No medicines are approved to treat it. Researchers need to test new medicines to see if they help people recover from Ebola and are safe to give. They need to test the drugs and compare them in a controlled way. Researchers want to test 3 drugs with people who have Ebola and are in treatment centers. Objective: To study the safety and effectiveness of 3 drugs for people with Ebola virus. Eligibility: People of any age with Ebola infection who are in treatment centers Design: Participants will be screened with questions, medical history, and blood tests. Participants will be randomly assigned to get 1 of 3 study drugs: - ZMapp by IV over about 4 hours. It will be given 3 times, 3 days apart. - Remdesivir by IV over about 1 hour. It will be given once a day for 10 days. - Mab114 by IV for 30-60 minutes. It will be given 1 time. For at least a week, participants will stay in isolation in a clinic. They will: - Get supportive care and be monitored - Have a small plastic tube (IV) put in an arm vein for several days to give fluids and collect blood. - Get their study drug. - Be monitored for disease signs and drug side effects. They may get medicines for side effects. - Have blood and urine tests. Participants will stay in the clinic until they finish the study drug and are well enough to leave. Participants will have 2 follow-up visits over 2 months. They will answer questions and give blood and semen samples.
NCT04252664 Mild/Moderate 2019-nCoV Remdesivir RCT Not yet recruiting Chinese Academy of Medical Sciences Phase 3 2020-02-05 In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (2019-nCoV) from these pneumonia patients and developed a real-time reverse transcription PCR (real time RT-PCR) diagnostic assay. Given no specific antiviral therapy for 2019-nCoV infection and the availability of remdesvir as a potential antiviral agent based on pre-clinical studies in SARS-CoV and MERS-CoV infections, this randomized, controlled, double blind trial will evaluate the efficacy and safety of remdesivir in patients hospitalized with mild or moderate 2019-nCoV respiratory disease.
NCT04252664 Mild/Moderate 2019-nCoV Remdesivir RCT Not yet recruiting Capital Medical University Phase 3 2020-02-05 In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (2019-nCoV) from these pneumonia patients and developed a real-time reverse transcription PCR (real time RT-PCR) diagnostic assay. Given no specific antiviral therapy for 2019-nCoV infection and the availability of remdesvir as a potential antiviral agent based on pre-clinical studies in SARS-CoV and MERS-CoV infections, this randomized, controlled, double blind trial will evaluate the efficacy and safety of remdesivir in patients hospitalized with mild or moderate 2019-nCoV respiratory disease.
NCT04257656 Severe 2019-nCoV Remdesivir RCT Not yet recruiting Capital Medical University Phase 3 2020-02-05 In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia of unknown cause. In a short time, Chinese scientists had shared the genome information of a novel coronavirus (2019-nCoV) from these pneumonia patients and developed a real-time reverse transcription PCR (real time RT-PCR) diagnostic assay. Given no specific antiviral therapy for 2019-nCoV infection and the ready availability of remdesvir as a potential antiviral agent, based on pre-clinical studies in SARS-CoV and MERS-CoV infections, this randomized, controlled, double blind trial will evaluate the efficacy and safety of remdesivir in patients hospitalized with severe 2019-nCoV respiratory disease.
NCT04280705 Adaptive COVID-19 Treatment Trial Not yet recruiting National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 2020-03-12 This study is an adaptive, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of novel therapeutic agents in hospitalized adult patients diagnosed with COVID-19. The study is a multicenter trial that will be conducted in up to 50 sites globally. The study will be a series of 2-arm comparisons between different investigational therapeutic agents and a placebo. There will be interim monitoring to introduce new arms and allow early stopping for futility, efficacy, or safety. If one therapy proves to be efficacious, this treatment will then become the control arm for comparison(s) with new experimental treatment(s). Because of the possibility that background standards of supportive care may evolve/improve over time as more is learned about successful management of COVID-19, comparisons of safety and efficacy will be based on data from concurrently randomized participants. An independent data and safety monitoring board (DSMB) will actively monitor interim data to make recommendations about early study closure or changes to study arms. Randomization will be stratified by: 1) site and 2) severity of illness at enrollment, severe disease (requiring mechanical ventilation or oxygen, a SpO2 /= 24 breaths/min)) or mild-moderate disease (SpO2 > 94% and respiratory rate < 24 breaths/min without supplemental oxygen)). Subjects will be assessed daily while hospitalized. Discharged patients will be asked to attend study visits at Days 15, and 29. All subjects will undergo a series of efficacy, safety, and laboratory assessments. The primary objective of the study is to evaluate the clinical efficacy of different investigational therapeutics relative to the control arm in patients hospitalized with COVID-19.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Remdesivir

Condition Name

Condition Name for Remdesivir
Intervention Trials
COVID-19 29
Covid19 20
Corona Virus Infection 5
Pneumonia, Viral 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Remdesivir
Intervention Trials
Coronavirus Infections 21
Severe Acute Respiratory Syndrome 14
Pneumonia 8
Virus Diseases 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Remdesivir

Trials by Country

Trials by Country for Remdesivir
Location Trials
United States 70
Spain 5
Bangladesh 4
Pakistan 4
Brazil 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Remdesivir
Location Trials
California 8
North Carolina 5
New York 4
Maryland 4
Arizona 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Remdesivir

Clinical Trial Phase

Clinical Trial Phase for Remdesivir
Clinical Trial Phase Trials
Phase 4 2
Phase 3 28
Phase 2/Phase 3 10
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Remdesivir
Clinical Trial Phase Trials
Not yet recruiting 46
Recruiting 25
Completed 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Remdesivir

Sponsor Name

Sponsor Name for Remdesivir
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 9
Gilead Sciences 6
Hospital Universitario Nacional de Colombia 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Remdesivir
Sponsor Trials
Other 123
Industry 17
NIH 14
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Moodys
AstraZeneca
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.